Shinya Ueda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shinya Ueda has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- David W. Boulton
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Gaithersburg Maryland USA
1 shared publication - Joanna Parkinson
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden
1 shared publication Masamichi Shimamura
Department of Radiological Technology College of Medical Science Kumamoto University
1 shared publication- Robert Penland
Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts
1 shared publication Takehiro Uchida
Department of Radiology, Amano Plastic Surgery
1 shared publication- Tatiana Yakovleva
M&S Decisions Moscow Russia
1 shared publication
Latest Publications
- Open Access
- 19 November 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (4) , 829-836
Urinary glucose excretion after dapagliflozin treatment: An exposure‐response modelling comparison between Japanese and non‐Japanese patients diagnosed with type 1 diabetes mellitus
Aims: To assess the dapagliflozin exposure‐response relationship in Japanese and non‐Japanese patients with type 1 diabetes mellitus (T1DM) and investigate if a dose adjustment is required in Japanese patients. Materials and Methods: Data from two clinical studies were used to develop a non‐linear mixed effects model describing the relationship between dapagliflozin exposure (area under the concentration curve) and response (24‐hour urinary glucose excretion [UGE]) in Japanese and non‐Japanese patients with T1DM. The effects of patient‐level characteristics (covariates; identified using a stepwise procedure) on response was also assessed. Simulations were performed using median‐normalized covariate values. Results: Data from 84 patients were included. Average self‐monitored blood glucose (SMBG) at day 7, change from baseline in total insulin dose at day 7, and baseline estimated glomerular filtration rate (eGFR) all had a significant effect on 24‐hours UGE, with SMBG being the most influential. Dapagliflozin systemic exposure for matching doses and baseline eGFR was similar between Japanese and non‐Japanese patients; however, higher SMBG and a greater reduction in total insulin dose was observed in the Japanese population. When the significant covariates were included, the model fit the data well for both populations, and accurately predicted exposure‐response in the Japanese and non‐Japanese populations, in agreement with the observed data. Conclusions: There was no difference in dapagliflozin exposure‐response in Japanese and non‐Japanese patients with T1DM once differences in renal function, glycaemic control and insulin dose reductions between studies were considered. Therefore, no dose adjustment is recommended in Japanese patients with T1DM.
- 19 November 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (4) , 829-836
Open AccessUrinary glucose excretion after dapagliflozin treatment: An exposure‐response modelling comparison between Japanese and non‐Japanese patients diagnosed with type 1 diabetes mellitus
Aims: To assess the dapagliflozin exposure‐response relationship in Japanese and non‐Japanese patients with type 1 diabetes mellitus (T1DM) and investigate if a dose adjustment is required in Japanese patients. Materials and Methods: Data from two clinical studies were used to develop a non‐linear mixed effects model describing the relationship between dapagliflozin exposure (area under the concentration curve) and response (24‐hour urinary glucose excretion [UGE]) in Japanese and non‐Japanese patients with T1DM. The effects of patient‐level characteristics (covariates; identified using a stepwise procedure) on response was also assessed. Simulations were performed using median‐normalized covariate values. Results: Data from 84 patients were included. Average self‐monitored blood glucose (SMBG) at day 7, change from baseline in total insulin dose at day 7, and baseline estimated glomerular filtration rate (eGFR) all had a significant effect on 24‐hours UGE, with SMBG being the most influential. Dapagliflozin systemic exposure for matching doses and baseline eGFR was similar between Japanese and non‐Japanese patients; however, higher SMBG and a greater reduction in total insulin dose was observed in the Japanese population. When the significant covariates were included, the model fit the data well for both populations, and accurately predicted exposure‐response in the Japanese and non‐Japanese populations, in agreement with the observed data. Conclusions: There was no difference in dapagliflozin exposure‐response in Japanese and non‐Japanese patients with T1DM once differences in renal function, glycaemic control and insulin dose reductions between studies were considered. Therefore, no dose adjustment is recommended in Japanese patients with T1DM.
- Open Access
- 1 January 1992
- Published by Japanese Society of Radiological Technology in Japanese Journal of Radiological Technology
- Vol. 48 (6) , 880-884
STORAGE STABILITY AND GRAININESS OF HYPERSENSITIZED X-RAY FILM BY RORMING GAS
- 1 January 1992
- Published by Japanese Society of Radiological Technology in Japanese Journal of Radiological Technology
- Vol. 48 (6) , 880-884
Open AccessSTORAGE STABILITY AND GRAININESS OF HYPERSENSITIZED X-RAY FILM BY RORMING GAS